NTT to Extend the World’s Largest Connected Stadium to The Tour de France Femmes avec Zwift
28.6.2022 07:00:00 EEST | Business Wire | Press release
NTT Ltd., a leading IT infrastructure and services company, is using technology and innovation to equally enhance the fan experience across both the Tour de France and the Tour de France Femmes avec Zwift.
The 2022 event will see the inaugural women’s race which will start on the Champs-Élysées on July 24th 2022, prior to the conclusion of the men’s race on the same day. The women’s race will feature 24 teams of six riders and will conclude on July 31st 2022 in La Super Planche des Belles Filles. NTT has been the official technology partner of the Tour de France for the past eight years.
For the first time ever, and at a time when interest in women’s cycling is on the rise, NTT will bring fans closer to the action and shine a light on this notable occasion through the implementation of real-time tracking of the riders, the Race Center and its predictive modelling strategy to support the race. The model also includes @letourdata, the data-driven content channel that helps tell the race’s stories over social media and broadcast. Rider and team profiles will uncover unique insights into the women’s pro peloton.
In addition to this, NTT alongside A.S.O. will deliver a host of new and enhanced digital experiences to engage fans around the world, both at home and along the roadside. These experiences include:
- The Digital Human: NTT has developed an interactive kiosk featuring an AI-generated realistic human avatar, trained on the relevant race and tourist information. This technology will be deployed at the official fan store at the Grand Depart in Copenhagen and in NTT’s Technical Truck at the end of every stage.
- An enhanced digital twin: Last year, NTT created a digital twin of the event, which enabled staff to gain real-time visibility and ultimately streamline operations to ensure the continuity and resilience of the race. This year, the technology has enhanced connectivity to provide smarter event operations, enabling quicker, more informed decisions in a highly complex and ever-changing environment.
- Strava partnership: NTT’s live storytelling channel, @letourdata, in collaboration with Strava, will be bringing real-time comparisons between amateurs, pros, and King of the Mountain (or fastest known times) to social media and broadcast during the race.
“With female cycling on the rise as we saw through the 2020 edition of La Course by Le Tour de France avec FDJ with over 30 million TV audience viewers, we’re incredibly proud to continue to help widen the fan base and be part of this historic milestone for female cycling. There is still much more work to be done to achieve equality in cycling, but we’re extremely passionate about doing what we can to increase the accessibility of the sport. Our technology means we can bring the action to more fans than ever before,” says Michele McGuire, Vice President of Managed Services Delivery, Europe at NTT Ltd.
“When it comes to the technology, both races are highly dynamic and require access to real-time information to ensure continuous and smooth operations while creating more informed and engaged fans. NTT’s full stack of solutions and expertise will continue to support the A.S.O. in transforming the famous race,” McGuire adds.
“At A.S.O., we’re extremely proud to be launching Tour de France Femmes avec Zwift and to be able to count on key technical partners such as NTT. Our partnership with NTT is well known for bringing the fans closer to the action. 2022 marks a momentous occasion for women’s cycling, and fans around the world are extremely excited to witness the first edition of the Tour de France Femmes avec Zwift,” said Julien Goupil, Media & Partnerships Director at A.S.O..
NTT’s role as the official technology partner to Tour de France Femmes avec Zwift, means NTT will now support A.S.O. at four of its female events, including Paris-Roubaix Femmes avec Zwift, Flèche Wallonne Femmes, and Liège-Bastogne-Liège Femmes. To find out more about how NTT supports A.S.O., visit: https://services.global.ntt/tourdefrance
Follow @letourdata on Twitter and look for NTT’s race predictions using #NTTPredictor.
ENDS
About Amaury Sport Organisation
Amaury Sport Organisation is a company that owns, designs and organises top international sporting events. Specialised in the ‘non-stadia’ events, it has in-house knowledge of professions linked to organisation, media and sales of sports events. A.S.O. organises 250 days of competition per year, with 90 events in 30 countries. A.S.O. is involved in 5 major sports including cycling with the Tour de France, motor sports with the Dakar, mass events with the Schneider Electric Marathon de Paris, golf with the Lacoste Ladies Open de France and sailing with production and distribution of images for prestigious races. Amaury Sport Organisation is a subsidiary of the Amaury Group, media and sport group that owns the newspaper L’Équipe.
About NTT Ltd.
NTT Ltd. is a leading IT infrastructure and services company. With revenues of over USD 10 billion, we operate in more than 200 countries and regions, and serve 5,000 clients across multiple industries. Through technology and innovation, we deliver a secure and connected future that empowers our people, clients and communities. We lay the foundation for organizations’ edge-to-cloud networking ecosystem, simplify the complexity of their workloads across multicloud environments, and innovate at the edge of their IT environments, where networks, cloud and applications converge. On the journey towards a software-defined future, we support organizations with platform-delivered infrastructure services. As part of the global NTT Corporation, we serve 65% of the Fortune Global 500 and 80% of the Fortune Global 100. We enable a connected future.
Visit us at services.global.ntt
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220627005681/en/
Contact information
Media Inquiries:
Tour de France - www.letour.fr
Fabrice Tiano
ftiano@aso.fr - +33(0)6.33.86.28.64
Tour de France Femmes avec Zwift - www.letourfemmes.fr
Thida Vuillaume
tvuillaume@aso.fr - +33(0)6.40.29.69.26
Hotwire for NTT Ltd.
Hannah Lock
NTT@hotwireglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom